prostate cancer cells

[Clinical and Experimental Pharmacology and Physiology] The authors explored the effect of the upregulation or downregulation of the NPM1 protein on the malignancy of prostate cancer and its possible signaling pathway.

[Oncogene] PKCβ inhibition reduced total androgen receptor (AR) gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies.

[Molecular Cancer therapeutics] Scientists investigated the response of PTEN wild-type prostate cancer cell lines to the dual PI3K/mTOR inhibitor DS-7423 alone or in combination with HER2 inhibitors or mGluR1 inhibitors.

[Molecular Cancer Research] Using human cell lines that represent androgen-independent or -sensitive prostate cancer, the authors showed that mitochondrial Rho GTPase 2 (MIRO2) depletion impaired cell growth, colony formation, and tumor growth in mice.

[Cancer & Metabolism] As cholesterol is a key substrate for de novo steroidogenesis in prostate cells, researchers hypothesized that castrate-resistant/advanced prostate cancer cell growth was influenced by the availability of extracellular, low-density lipoprotein (LDL)-derived, cholesterol, which was coupled to intracellular cholesteryl ester homeostasis.

[Molecular Cancer therapeutics] Scientists performed transcriptomic analysis and confirmed that fractionated ionizing radiation (FIR)-induced neuroendocrine (NE)-like cells share some features of clinical NE prostate cancer, suggesting that FIR-induced NE differentiation represents a clinically-relevant model.